Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT01610141

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01610141
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01610141. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
Condition
Heart Valve Disease
Intervention (Other)
Genotype-guided warfarin dosing
Intervention (Other)
Non-genotype guided warfarin dosing
Lead sponsor
Chinese PLA General Hospital (class: other)

Record details

Record id
cardio:ct-nct01610141
Content hash
2a212f6a87ae35f977192343c2b17924838ddaa3e0122619818fc0c817b18431